Governments are investing billions of dollars preparing for potential bioterrorism attacks and pandemic diseases. In the U.S., spending on military and civilian biodefense initiatives has averaged US$5.4 billion over the past decade, and the global market is expected to reach US$17 billion by 2024.
Billions allocated for strategic stockpiles
Governments and military agencies represent the primary market for the AntoXa products. These agencies have large budgets for developing and stockpiling medical countermeasures. For examples, the Strategic National Stockpile in the United States has been allocated US$50 billion snice 2001 to create a national repository of life-saving pharmaceuticals, including chemical antidotes and antitoxins. AntoXa, through PlantForm, has established positive relationships with the Canadian, American and Australian departments of defence and has to date secured greater than $3.8 million towards its medical countermeasure programs.